Polartec LLC to License Stay-Fresh(R) Antimicrobial Technology

GAINESVILLE, FL--(Marketwired - August 27, 2013) -  Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it has signed a license for a range of products and fields of use with Polartec LLC, a premium producer of textile solutions. 

"We are very pleased to enter into this partnership with such a strongly positioned and technologically advanced partner as Polartec, whose leadership and innovation in performance textiles is recognized worldwide. Our Stay Fresh technology can permit Polartec to unlock added value in their product offerings, as well as access entire new segments with their performance fabrics, and strong network of industrial partners," said Bernd Liesenfeld, Quick-Med's President. 

About Stay Fresh

Stay Fresh is Quick-Med's newest technology platform. This technology is based on hydrogen peroxide -- a well known consumer antimicrobial product that is commonly used in households for disinfecting cuts, scrapes, toothbrushes and more. Hydrogen peroxide is also produced by human cells to combat invasive bacteria, and is a naturally occurring preservative component of milk and honey. EPA has registered Stay Fresh to be utilized to protect a broad selection of treated goods for consumer use, including textiles, decorative fabrics, and functional fabrics such as filters and carpets. FDA has also granted clearance to market an antibacterial medical textile based on Stay Fresh Technology. The Stay Fresh technology offerings provided by Quick-Med are expanding continuously, with development of additional applications including antimicrobial surface treatments, and superabsorbent antimicrobial powders to complement the range of products that are already cleared for consumer use under EPA or FDA jurisdiction.

About Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc. is a life sciences company that is developing and commercializing proprietary, broad-based technologies for the consumer and healthcare markets. The Company's NIMBUS® technology is the first FDA-cleared, non-leaching antimicrobial technology available in a wound dressing. Its Stay Fresh® technology provides highly durable antimicrobial protection for apparel and other textile applications, with consumer applications of Stay Fresh Technology having EPA registration for the treated articles, as well as an FDA clearance for an antibacterial medical textile product. Quick-Med develops antimicrobial technologies to promote public health, safety and comfort. For more information, see: www.quickmedtech.com.

About Polartec, LLC

Polartec, LLC is the premium producer of innovative textile solutions. Since inventing modern synthetic fleece in 1981, the engineers at Polartec have continued to push the limits of fabric technology. Today, Polartec supplies the world with the most advanced fabric innovations. Polartec products range from advanced lightweight wicking fabric, to insulation and weather protection textiles and are utilized by leading apparel brands, the U.S. military and other global militaries, flame resistance, work wear, and contract upholstery markets. For more information, visit polartec.com. 

© 2013 Quick-Med Technologies, Inc. All rights reserved. NIMBUS®, and Stay Fresh® are registered trademarks of Quick-Med Technologies, Inc.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.

CONTACT: Quick-Med Technologies Bernd Liesenfeld, President [phone] [e-mail]